Zobrazeno 1 - 10
of 237
pro vyhledávání: '"Hans-Juergen Woerle"'
Autor:
Timothy Nicholas Fazio, Louise Healy, Tim Heise, Anita Inwood, Catherine Manolikos, Yusof Rahman, Hans-Juergen Woerle, Christian J. Hendriksz
Publikováno v:
Molecular Genetics and Metabolism Reports, Vol 37, Iss , Pp 101012- (2023)
The cornerstone treatment of hyperphenylalaninemia (HPA) and phenylketonuria (PKU) is a lifelong low-protein diet with phenylalanine (Phe) free L-amino acid supplements. However, the PKU diet has significant shortcomings, and there is a clinically un
Externí odkaz:
https://doaj.org/article/e8398e8fcb364d829a0c08abebf5f4a0
Autor:
Julio Rosenstock, Vlado Perkovic, John H. Alexander, Mark E. Cooper, Nikolaus Marx, Michael J. Pencina, Robert D. Toto, Christoph Wanner, Bernard Zinman, David Baanstra, Egon Pfarr, Michaela Mattheus, Uli C. Broedl, Hans-Juergen Woerle, Jyothis T. George, Maximilian von Eynatten, Darren K. McGuire, CARMELINA® investigators
Publikováno v:
Cardiovascular Diabetology, Vol 17, Iss 1, Pp 1-15 (2018)
Abstract Background Cardiovascular (CV) outcome trials in type 2 diabetes (T2D) have underrepresented patients with chronic kidney disease (CKD), leading to uncertainty regarding their kidney efficacy and safety. The CARMELINA® trial aims to evaluat
Externí odkaz:
https://doaj.org/article/4f753d01958c432990f07fa12eea7bb6
Autor:
Bruce A Perkins, David Z I Cherney, Nima Soleymanlou, Justin A Lee, Helen Partridge, Holly Tschirhart, Bernard Zinman, Roger Mazze, Nora Fagan, Stefan Kaspers, Hans-Juergen Woerle, Uli C Broedl, Odd Erik Johansen
Publikováno v:
PLoS ONE, Vol 10, Iss 11, p e0141085 (2015)
We recently reported improved glycemic control with reduced insulin dose in subjects with type 1 diabetes treated with the sodium glucose co-transporter-2 inhibitor empagliflozin. To further characterize the effects, we analyzed diurnal glycemic patt
Externí odkaz:
https://doaj.org/article/b2c437cf61584b079e016ba149dba298
Autor:
Hans-Juergen Woerle, Sanjay Patel
Publikováno v:
Drug, Healthcare and Patient Safety, Vol 2010, Iss default, Pp 93-94 (2010)
Hans-Juergen Woerle, Sanjay PatelBoehringer Ingelheim GmbH, GermanyDear Dr Zhou,Boehringer Ingelheim, owner of the investigational drug linagliptin, would like to point out that in the recent review paper by Cox and colleagues,1 titled “Dipeptidyl
Externí odkaz:
https://doaj.org/article/d616ef858d664b22b4a1a85b11d1a196
Autor:
Uli C. Broedl, Jyothis T. George, Ruth L. Coleman, Bernard Zinman, Alastair Gray, Hans-Juergen Woerle, David Fitchett, Rury R. Holman
Aim To perform post‐hoc analyses of the EMPA‐REG OUTCOME trial examining the degree to which empagliflozin‐induced changes in conventional cardiovascular (CV) risk factors might explain the observed CV benefits. Materials and methods We estimat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0eb12b91d664fe77d8115537c523ecbf
https://ora.ox.ac.uk/objects/uuid:f3c4e8d9-937b-4c7c-bbb6-2352aecfbdb9
https://ora.ox.ac.uk/objects/uuid:f3c4e8d9-937b-4c7c-bbb6-2352aecfbdb9
Publikováno v:
Diabetes Care. 41:1809-1816
OBJECTIVE To assess the effect of empagliflozin on bone fractures and bone mineral density in patients with type 2 diabetes in pooled placebo-controlled trial data and a head-to-head study versus glimepiride. RESEARCH DESIGN AND METHODS Pooled data w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10e784beb10e625e9de83d8999876996
https://doi.org/10.2337/dc17-1525
https://doi.org/10.2337/dc17-1525
Autor:
Jyothis T. George, Maximilian von Eynatten, Michaela Mattheus, Bernard Zinman, Uli C. Broedl, David Fitchett, Silvio E. Inzucchi, Christoph Wanner, John M. Lachin, Hans-Juergen Woerle
Publikováno v:
Circulation. 137:119-129
Background: Empagliflozin, a sodium-glucose cotransporter 2 inhibitor, reduced cardiovascular morbidity and mortality in patients with type 2 diabetes mellitus and established cardiovascular disease in the EMPA-REG OUTCOME trial (Empagliflozin Cardio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84eb3c9ed950f8a2794d6440be5fafcb
https://doi.org/10.1161/circulationaha.117.028268
https://doi.org/10.1161/circulationaha.117.028268
Autor:
Christoph Wanner, John M. Lachin, Philippe van de Borne, Uli C. Broedl, Bernard Zinman, Odd Erik Johansen, David Fitchett, Empa-Reg Outcome Investigators, Jyothis T. George, Hans-Juergen Woerle, Michaela Mattheus, Silvio E. Inzucchi
Publikováno v:
Journal of the American College of Cardiology. 71:364-367
Diabetes is associated with a significant decrease in life expectancy [(1)][1]. In the EMPA-REG OUTCOME trial ([NCT01131676][2]), empagliflozin given in addition to standard of care reduced the risk of cardiovascular death by 38% (hazard ratio [HR]:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a099b47d047eb042688c6ed57c266a50
https://doi.org/10.1016/j.jacc.2017.11.022
https://doi.org/10.1016/j.jacc.2017.11.022
Autor:
Ilkka Tikkanen, David Z.I. Cherney, Hans-Juergen Woerle, Søren S Lund, Egon Pfarr, Mark E. Cooper, Odd Erik Johansen, Uli C. Broedl
Publikováno v:
Kidney International. 93:231-244
Sodium glucose cotransporter 2 (SGLT2) inhibitors reduce HbA1c, blood pressure, and weight in patients with type 2 diabetes. To investigate the effect of renal function on reductions in these parameters with the SGLT2 inhibitor empagliflozin, we asse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af3de3158d17db311d1e6db4bd0559a2
https://doi.org/10.1016/j.kint.2017.06.017
https://doi.org/10.1016/j.kint.2017.06.017
Autor:
Julio Rosenstock, Uli C. Broedl, Nikolaus Marx, Jyothis T. George, Hans-Juergen Woerle, Maximilian von Eynatten, Vlado Perkovic, Darren K. McGuire
Publikováno v:
Diabetes Care. 40:1144-1151
Reductions in cardiovascular (CV) outcomes in recently reported trials, along with the recent approval by the U.S. Food and Drug Administration of an additional indication for empagliflozin to reduce the risk of CV death in type 2 diabetes patients w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f6f864765eaddba8f70fce4a850f144
https://doi.org/10.2337/dc17-0068
https://doi.org/10.2337/dc17-0068